Ampicillin and Sulbactam for Injection, USP
Ampicillin and Sulbactam for Injection, USP is an injectable antibacterial combination consisting of the semisynthetic antibiotic ampicillin sodium and the beta-lactamase inhibitor sulbactam sodium for intravenous and intramuscular administration. Ampicillin sodium is derived from the penicillin nucleus, 6-aminopenicillanic acid.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin and Sulbactam for Injection and other antibacterial drugs, Ampicillin and Sulbactam for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Ampicillin and Sulbactam for Injection is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below.
Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli, Efficacy for this organism in this organ system was studied in fewer than 10 infections. Klebsiella spp. (including K. pneumoniae ), Proteus mirabilis, Bacteroides fragilis , Enterobacter spp., and Acinetobacter calcoaceticus.
NOTE: For information on use in pediatric patients see PRECAUTIONS—Pediatric Use and CLINICAL STUDIES sections.
Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. pneumoniae ), Bacteroides spp. (including B. fragilis), and Enterobacter spp.
Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli, and Bacteroides spp. (including B. fragilis ).
While Ampicillin and Sulbactam for Injection is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with Ampicillin and Sulbactam for Injection due to its ampicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and beta-lactamase producing organisms susceptible to Ampicillin and Sulbactam for Injection should not require the addition of another antibiotic.
Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to Ampicillin and Sulbactam for Injection.
Therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies, when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above in the indicated organ systems. Once the results are known, therapy should be adjusted if appropriate.
Published Studies Related to Ampicillin and Sulbactam (Ampicillin / Sulbactam)
A prospective, multi centre, randomized clinical study to compare the efficacy and safety of Ertapenem 3 days versus Ampicillin-Sulbactam 3 days in the treatment of localized community acquired intra-abdominal infection. (T.E.A. Study: Three days Ertapenem vs three days Ampicillin-sulbactam). [2011.04.18]
BACKGROUND: The recommendations outlined in the latest guidelines published by the Surgical Infection Society (SIS) and the Infectious Disease Society of America (IDSA) regarding the proper duration of antibiotic therapy in patients with intra-abdominal infections are limited and non-specific.
Ampicillin/sulbactam versus cefuroxime as antimicrobial prophylaxis for cesarean delivery: a randomized study. [2010.11.30]
BACKGROUND: The efficacy and safety of a single dose of ampicillin/sulbactam compared to a single dose of cefuroxime at cord clamp for prevention of post-cesarean infectious morbidity has not been assessed... CONCLUSIONS: Ampicillin/sulbactam was as safe and effective as cefuroxime when administered for the prevention of infections following cesarean delivery. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT01138852.
Piperacillin/tazobactam plus ceftazidime versus sulbactam/ampicillin plus aztreonam as empirical therapy for fever in severely neutropenic pediatric patients. [2009.04]
CONCLUSIONS: PIPC/TAZ+CAZ and SBT/ABPC+AZT are effective and safe for initial empirical treatment of febrile episodes in neutropenic pediatric patients. The clinical efficacy of SBT/ABPC+AZT is equivalent or superior to that of PIPC/TAZ+CAZ, the effect of which is already proven against febrile neutropenia. Therefore, SBT/ABPC+AZT may be a treatment of choice for febrile neutropenia in pediatric cancer patients.
High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii. 
The increased incidence of multidrug-resistant (MDR) Acinetobacter baumannii ventilator-associated pneumonia in critically ill patients poses a severe therapeutic problem. The aim of this study was to evaluate the efficacy and safety of 2 high-dose treatment regimens of ampicillin-sulbactam (A/S) for MDR Acinetobacter baumannii VAP...
The value of chemoprophylaxis against Enterococcus species in elective cholecystectomy: a randomized study of cefuroxime vs ampicillin-sulbactam. [2006.12]
HYPOTHESIS: Cephalosporins are widely used and considered to be effective as prophylaxis in biliary surgery. Nevertheless, they lack activity against enterococci. We conducted a study to compare the efficacy of ampicillin-sulbactam vs cefuroxime in preventing surgical site infections following elective cholecystectomy... CONCLUSIONS: A single dose of ampicillin-sulbactam favored better compared with cefuroxime for prevention of postoperative surgical site infections due to Enterococcus species after elective cholecystectomy. Ampicillin-sulbactam may be a better agent for antimicrobial prophylaxis in high-risk patients undergoing elective cholecystectomy, especially in a setting where the incidence of enterococcal infections is higher.
Clinical Trials Related to Ampicillin and Sulbactam (Ampicillin / Sulbactam)
Comparison of Ampicillin / Sulbactam vs. Ampicillin / Gentamicin for Treatment of Intrapartum Chorioamnionitis: a Randomized Controlled Trial [Recruiting]
Chorioamnionitis is an infection of the placenta and amniotic membranes (bag of waters)
surrounding the baby inside of a pregnant woman prior to delivery. This infection is
somewhat common and is routinely treated with antibiotics given to the mother both before
and after the baby is born. Currently it is not known what is the best choice of antibiotics
to treat this type of infection, but commonly used treatments include Unasyn
(ampicillin/sulbactam) or ampicillin/gentamicin. We plan to compare these two different
antibiotic regimens to see if one is better than the other at treating and preventing bad
outcomes from chorioamnionitis in women and babies.
Ampicillin for DYT-1 Dystonia Motor Symptoms [Recruiting]
The purpose of this study is to evaluate if the antibiotic Ampicillin is safe and tolerated
in patients that have generalized dystonia caused by the DYT-1 gene mutation, as compared to
patients treated with a placebo. A placebo is a pill that looks and tastes the same as the
real drug, but without the active ingredient. The second objective of this study is to
determine if dystonia symptoms improve while on the study drug.
Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia [Recruiting]
The purpose of this study is to prove the clinical and bacteriological non-inferiority of
ampicillin/amoxicillin versus moxifloxacin in hospitalized patients with non-severe
Zithromax EV in Community-Acquired Pneumonia (CAP) [Completed]
The intravenous (IV) regimen containing azithromycin (Zithromax) plus ampicillin-sulbactam is
consistent with current guidelines for the treatment of CAP. In fact the International
guidelines for the treatment of CAP in hospitalised patients suggests the use of a
combination between a b-lactam and a macrolide.
This trial will allow investigators to evaluate the efficacy of azithromycin plus
ampicillin-sulbactam in the treatment of hospitalized subjects with community acquired
pneumonia. In addition, this trial will allow investigators to evaluate the safety and
toleration of combination therapy.
A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections [Recruiting]
On the basis of monotherapy for intra-abdominal infection, the investigators are conducting
this study to identify the difference of drug efficacy between ampicillin/sulbactam and
Reports of Suspected Ampicillin and Sulbactam (Ampicillin / Sulbactam) Side Effects
Enterocolitis Haemorrhagic (14),
Culture Stool Positive (9),
Klebsiella Infection (6),
Urinary Tract Infection (6),
Benign Prostatic Hyperplasia (6),
Klebsiella Test Positive (6),
Pyrexia (4), more >>
Page last updated: 2011-12-09